Answer
Martin Shkreli, the CEO of Turing Pharmaceuticals, sparked outrage in September 2015 by hiking the price of Daraprim, a 62-year-old drug used to treat a parasitic infection, from $13.50 to $750 per pill, an increase of over 5,000%. This decision drew widespread criticism, with many accusing Shkreli of price gouging and exploiting patients' health for profit.